Search clinical trials for: NBI/BLI /- chromoendoscopy (NBIBLI /- CE)

Total 1297 results

Althaia Xarxa Assistencial Universitària de Manresa
Hospital Clinic of Barcelona; University of North Carolina, Chapel Hill; Germans... and other collaborators

Completed

Accuracy for Predicting Deep Submucosal Invasion (NBIBLI)

Colorectal Cancer | Colorectal Polyp

Spain, United States, Japan
Universitaire Ziekenhuizen KU Leuven
McGill University; Maastricht University Medical Center; Copenhagen University... and other collaborators

Unknown

Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis

Ulcerative Colitis

Belgium, Canada, Denmark, Netherlands
Maria Sklodowska-Curie National Research Institute...
Centre of Postgraduate Medical Education

Completed

The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck | Esophageal Squamous Cell Carcinoma

Poland
Vastra Gotaland Region

Recruiting

Improved and Simplified Staining Technique for Dysplasia Detection in Colitis (IST-DDC)

Inflammatory Bowel Diseases | Colitis | Colonoscopy | Surveillance | Colonic Dysplasia

Sweden
Asan Medical Center
Samsung Medical Center; Yonsei University; Ewha Womans University; The Catholic... and other collaborators

Unknown

Surveillance in Ulcerative Colitis: Narrow Band Image Versus Chromoendoscopy for High-risk Groups (SUNRISE-High)

Ulcerative Colitis | Dysplasia
Changhai Hospital
The Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaborators

Recruiting

Narrow Band Imaging Versus White Light for the Detection and Miss of Sessile Serrated Lesion

Colorectal Sessile Serrated Lesion

China
Botanix Pharmaceuticals

Completed

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Botanix Pharmaceuticals

Completed

A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumors

United States
Istituti Clinici Scientifici Maugeri SpA
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Completed

Italian Validation of the Beaumont Behavioural Inventory (BBI) (BBI)

Amyotrophic Lateral Sclerosis

Italy
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Yale University

Completed

Combination SBIRT for Emergency Department Patients Who Drink and Smoke

Smoking | Drinking

United States
US Department of Veterans Affairs

Completed

Veterans Intensive Personalized Treatment in Heart Failure (VIP)

Heart Failure

United States
Botanix Pharmaceuticals

Completed

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Healthy | ADME

United States
Rachel Miller

Completed

Biobehavioral Intervention in Gynecologic Oncology Patients

Neoplasms | Uterine Neoplasms | Ovarian Neoplasms | Vulva

United States
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
HonorHealth Research Institute
Neolight

Completed

Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns

Neonatal Hyperbilirubinemia | Jaundice, Neonatal | Neonatal Disorder

United States
Boundless Bio

Recruiting

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications (STARMAP)

Solid Tumor

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Canada
Sumitomo Pharma America, Inc.

Withdrawn

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Renal Cell Carcinoma | Urothelial Carcinoma | Urologic Malignancies
Sumitomo Pharma America, Inc.

Terminated

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

Cancer | Ovarian Cancer

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma

Canada
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (CARDIGANII)

Axillary Hyperhidrosis

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Recruiting

Promoting Alcohol Treatment Engagement Post-hospitalization (ENHANCE)

Alcohol Use Disorder

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (Cardigan I)

Axillary Hyperhidrosis

United States
Boston Medical Center

Completed

Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention

Cervical Cancer | Vulvar Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | Human Papillomavirus Infection | Human Papilloma Virus

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack (IRI-EXPLORE)

Myocardial Infarction

Korea, Republic of, Germany, Spain, Hungary, United Kingdom, Italy, Canada, Australia, Poland, Slovakia, New Zealand
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood

Healthy

Germany

3

Subscribe